

Prof. Pinar Mualla SAİP

Personal Information

Office Phone: [+90 212 414 2434](tel:+902124142434) Extension: 34225

Fax Phone: [+90 212 534 8078](tel:+902125348078)

Email: pinar@istanbul.edu.tr

Web: <http://aves.istanbul.edu.tr/1242/>

International Researcher IDs

ORCID: 0000-0001-6871-8519

Publons / Web Of Science ResearcherID: AAT-1500-2020

Yoksis Researcher ID: 101918

Education Information

Post Doctorate of Medicine, Istanbul University, Onkoloji Enstitüsü, Klinik Onkoloji Ana Bilim Dalı, Turkey 1993 - 1996

Expertise In Medicine, Istanbul University, Onkoloji Enstitüsü, Klinik Onkoloji Ana Bilim Dalı, Turkey 1988 - 1992

Undergraduate, Istanbul University, Onkoloji Enstitüsü, Klinik Onkoloji Ana Bilim Dalı, Turkey 1978 - 1984

Foreign Languages

French, B2 Upper Intermediate

English, C1 Advanced

Dissertations

Postgraduate, Evre III Over kanserlerinde intraperitoneal kemoterapinin yeri, Istanbul University, Onkoloji Enstitüsü, Klinik Onkoloji/Tıbbi Onkoloji Anabilim Dalı, 1995

Research Areas

Medicine, Health Sciences, Internal Medicine Sciences, Internal Diseases , Oncology

Academic Titles / Tasks

Professor, Istanbul University, Onkoloji Enstitüsü, Klinik Onkoloji Ana Bilim Dalı, 2003 - Continues

Associate Professor, Istanbul University, Onkoloji Enstitüsü, Klinik Onkoloji Ana Bilim Dalı, 1998 - 2003

Academic and Administrative Experience

İstanbul Üniversitesi, Onkoloji Enstitüsü, 2010 - 2012

İstanbul Üniversitesi, Onkoloji Enstitüsü, 2006 - 2010

İstanbul Üniversitesi, Onkoloji Enstitüsü, 2003 - 2008

Courses

MEME KANSERLERİNİN KLİNİĞİ, Doctorate, 2013 - 2014
ENDOMETRİUM TÜMÖRLERİ, Postgraduate, 2013 - 2014
3.SINIF UYGULAMA DERSİ, Undergraduate, 2013 - 2014
EĞİTİM DANIŞMANLIĞI OLGU SUNUMU, Doctorate, 2013 - 2014
5.SINIF VAKA DEMONSTRASYONLARI, Undergraduate, 2013 - 2014
DAHİLİYE İNTÖRNÜ ASİSTAN EĞİTİMİ, Doctorate, 2013 - 2014
OVER TÜMÖRÜ, Postgraduate, 2013 - 2014
4.SINIF OVER KANSERLERİNDE KEMOTERAPİ, Undergraduate, 2013 - 2014

Advising Theses

SAİP P. M., MEME KANSERLİ KADINLARDA SERUM HER2 VE CD44 DÜZEYİNİN KLİNİKOPATOLOJİK PARAMETRELER İLE KORELASYONU VE SAĞKALIM ÜZERİNE ETKİSİ, Expertise In Medicine, F.Aydoğan(Student), 2012

Jury Memberships

Associate Professor Exam, ÜLKÜ YALÇINTAŞ ARSLAN, MALTEPE ÜNİVERSİTESİ, October, 2011
Associate Professor Exam, BALA BAŞAK USTAALİOĞLU, MALTEPE ÜNİVERSİTESİ, October, 2011

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Germline mutational variants of Turkish ovarian cancer patients suspected of Hereditary Breast and Ovarian Cancer (HBOC) by next-generation sequencing.**
TUNÇER Ş. B., Çelik B., KILIÇ ERCİYAS S., Erdogan O. S., Gültaslar B. K., Odemis D. A., Avsar M., Sen F., SAİP P. M., Yazici H.
Pathology, research and practice, vol.254, pp.155075, 2024 (SCI-Expanded)
- II. **Comparative analysis of doublet chemotherapy regimens plus bevacizumab in patients with recurrent ovarian cancer**
Khanmammadov N., Doğan I., Okay N. S., AZİZY A., Saip P., AYDINER A.
Medicine (United States), vol.103, no.1, 2024 (SCI-Expanded)
- III. **Outcomes of the patients with metastatic male breast cancer**
Dogan I., Khanmammadov N., ÖZKURT S., AYDINER A., Saip P.
Journal of Cancer Research and Therapeutics, vol.20, no.1, pp.98-102, 2024 (SCI-Expanded)
- IV. **The effect of parity, breastfeeding history, and duration on clinical and pathological characteristics of breast cancer patients**
Ak N., Tuz Z., Aydin E., Ferhatoğlu F., SARI M., Paksoy N., Doğan I., Yildiz A., Dişçi R., Saip P. M.
Turkish Journal of Medical Sciences, vol.54, no.1, pp.229-238, 2024 (SCI-Expanded)
- V. **Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression**
DOĞAN İ., Aydin E., KHANMAMMADOV N., Paksoy N., Saip P., AYDINER A.
Scientific Reports, vol.13, no.1, 2023 (SCI-Expanded)
- VI. **Long-term outcomes and predictors of recurrence in node-negative early stage breast cancer patients**
DOĞAN İ., Aydin E., KHANMAMMADOV N., Paksoy N., Ferhatoğlu F., AK N., Emiroglu S., İBİŞ K., Onder S., Tukenmez M., et al.
Journal of Cancer Research and Clinical Oncology, vol.149, no.16, pp.14833-14841, 2023 (SCI-Expanded)

- VII. **Efficacy and outcomes of systemic chemotherapy in posttransplant and immunosuppression associated Kaposi sarcoma: Twenty years experience of a tertiary cancer center**
Khanmammadov N. A., Paksoy N., DOĞAN İ., Ferhatoglu F., Saip P., Aydiner A.
Medicine, vol.102, no.39, 2023 (SCI-Expanded)
- VIII. **Demographic and Clinical Features of Patients with Metastatic Breast Cancer: A Retrospective Multicenter Registry Study of the Turkish Oncology Group**
DOĞAN İ., AKSOY S., Cakar B., BAŞARAN G., Ercelep O., Molinas Mandel N., KORKMAZ T., Gokmen E., Sener C., AYDINER A., et al.
Cancers, vol.15, no.6, 2023 (SCI-Expanded)
- IX. **Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey**
Ünal Ç., Özmen T., Ordu Ç., Pilanci K. N., İlgün A. S., Gökmen E., Almuradova E., Özdoğan M., Güler N., URAS C., et al.
Frontiers in Oncology, vol.13, 2023 (SCI-Expanded)
- X. **Is Breast Conserving Surgery Efficacious in Breast Cancer Patients with BRCA1 or BRCA2 Germline Mutation?**
Emiroglu S., Özkurt E., Cabioglu N., Igci A., Saip P., YAZICI H., Ozmen T., Ozmen V., Muslumanoglu M., Tukenmez M.
Breast Cancer: Targets and Therapy, vol.15, pp.163-173, 2023 (SCI-Expanded)
- XI. **Evaluation of BRCA1/2 gene mutations in patients with high-risk breast and/or ovarian cancer in Turkey**
Akdeniz Odemis D., Celik B., Kilic Erciyas S., Sukruoglu Erdogan O., Tuncer S. B., Kurt Gultaslar B., Adamnejad Ghafour A., Saip P., Yazici H.
TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, vol.47, no.5, pp.588-594, 2022 (SCI-Expanded)
- XII. **The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study**
Dogan I., Ayhan M., Gurbuz M., Kucukarda A., Aydın E., ÜRÜN Y., ÇİÇİN İ., Saip P.
MEDICINE, vol.101, no.35, 2022 (SCI-Expanded)
- XIII. **Evaluation of clinicopathological features determining treatment response in patients with ALK mutant NSCLC**
DOĞAN İ., Gurbuz M., Paksoy N., Ferhatoglu F., Vatansever S., Saip P., DEMİRKAZIK A., Aydiner A.
MEDICINE, vol.101, no.34, 2022 (SCI-Expanded)
- XIV. **Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination.**
Dogan I., Paksoy N., Ak N., Vatansever S., Saip P., Aydiner A.
JOURNAL OF CLINICAL ONCOLOGY, vol.40, no.16, 2022 (SCI-Expanded)
- XV. **Are false-negative rates of sentinel lymph node biopsy after neoadjuvant chemotherapy really associated with poor prognosis in clinically node-positive disease at diagnosis?**
Cabioglu N., Karanlık H., Igci A., Muslumanoglu M., Tukenmez M., Emiroglu S., Ozkurt E., Yildirim N., Ilgun S., Onder S., et al.
ANNALS OF SURGICAL ONCOLOGY, vol.29, no.SUPPL 1, pp.310-311, 2022 (SCI-Expanded)
- XVI. **Prolongation of Neoadjuvant Chemotherapy before Surgery: Seeking the Optimal Number of Cycles in Serous Ovarian Cancer**
Minareci Y., Sozen H., Ak N., Tosun O. A., Saip P., Salihoglu M. Y., Topuz S.
CHEMOTHERAPY, vol.67, pp.1-11, 2022 (SCI-Expanded)
- XVII. **Skeletal system as a rare metastatic site in patients with ovarian carcinoma**
Ak N., Minareci Y., Saip P.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, vol.31, no.8, pp.1125-1131, 2021 (SCI-Expanded)
- XVIII. **Predictors of response in EGFR-mutant metastatic non-small cell lung cancer patients treated with tyrosine kinase inhibitors.**
Aydiner A., Dogan I., Khanmammadov N., Saip P., Vatansever S.
JOURNAL OF CLINICAL ONCOLOGY, vol.39, no.15, 2021 (SCI-Expanded)

- XIX. **Long-term outcomes and predictors of recurrence in patients with early-stage node negative breast cancer.**
Dogan I, Aydin E., Paksoy N., Ferhatoglu F., Ak N., Ibis K., Onder S., Tukenmez M., Cabioglu N., Muslumanoglu M., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.39, no.15, 2021 (SCI-Expanded)
- XX. **Outcomes of ROS1 positive metastatic lung cancer patients treated with crizotinib**
Dogan I, Khanmammadov N., Paksoy N., Ferhatoglu F., Aydin E., Vatansever S., Saip P., Aydiner A.
JOURNAL OF THORACIC ONCOLOGY, vol.16, no.4, 2021 (SCI-Expanded)
- XXI. **TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer**
Cabioglu N., Onder S., Oner G., Karatay H., Tukenmez M., Muslumanoglu M., Igci A., Eralp Y., Aydiner A., Saip P., et al.
BMC CANCER, vol.21, no.1, 2021 (SCI-Expanded)
- XXII. **Predictors of treatment response in ALK-positive metastatic non-small cell lung cancer**
Dogan I, Gurbuz M., Paksoy N., Ferhatoglu F., Vatansever S., Saip P., Demirkazik A., Aydiner A.
JOURNAL OF THORACIC ONCOLOGY, vol.16, no.4, 2021 (SCI-Expanded)
- XXIII. **Termination of trastuzumab-based treatment after complete response in HER2-positive metastatic breast cancer**
Dogan I, Aydin E., Khanmammadov N., Aydiner A., Saip P.
CANCER RESEARCH, vol.81, no.4, 2021 (SCI-Expanded)
- XXIV. **Does visceral adiposity have an effect on the survival outcomes of the patients with endometrial cancer?**
Celik E., Kizildag Yirgin I., Goksever Celik H., Engin G., Sozen H., Ak N., Saip P., Onder S., Topuz S., Salihoglu M. Y.
JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, vol.47, no.2, pp.560-569, 2021 (SCI-Expanded)
- XXV. **Outcomes of metastatic male breast cancer**
Dogan I., Khanmammadov N., Aydiner A., Saip P.
CANCER RESEARCH, vol.81, no.4, 2021 (SCI-Expanded)
- XXVI. **Tim3 expression on tumor infiltrating lymphocytes is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple negative breast cancer**
Cabioglu N., Onder S., Oner G., Karatay H., Tukenmez M., Muslumanoglu M., Igci A., Eralp Y., Aydiner A., Saip P., et al.
CANCER RESEARCH, vol.81, no.4, 2021 (SCI-Expanded)
- XXVII. **Comparison of clinicopathological features in BRCA-wild type and -mutated male breast cancer patients**
Dogan I., Aydin E., Yazici H., Saip P.
CANCER RESEARCH, vol.81, no.4, 2021 (SCI-Expanded)
- XXVIII. **Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience**
Bahceci A., PAYDAŞ S., Ak N., Ferhatoglu F., Saip P. M., SEYDAOĞLU G., BİLİCİ M., ŞİMŞEK M., TEKİN S. B., Calikusu Z., et al.
CANCER INVESTIGATION, vol.39, no.6-7, pp.473-481, 2021 (SCI-Expanded)
- XXIX. **Hormonal therapy in pretreated patients with metastatic or refractory ovary granulosa cell tumor**
Dogan I., Aydin E., Topuz S., Saip P., Salihoglu M. Y., Aydiner A.
ANNALS OF ONCOLOGY, vol.32, 2021 (SCI-Expanded)
- XXX. **Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial**
Demir A., Mandel N. M., PAYDAŞ S., Demir G., ER O., Turhal N. S., Bavbek S., Eralp Y., Saip P. M., Guler E. N., et al.
BALKAN MEDICAL JOURNAL, vol.37, no.2, pp.104-107, 2020 (SCI-Expanded)
- XXXI. **Eribulin monotherapy in heavily pretreated metastatic breast cancer patients in real life**
Sari M., Saip P.
INDIAN JOURNAL OF CANCER, vol.57, no.1, pp.55-61, 2020 (SCI-Expanded)
- XXXII. **IS CHEMOTHERAPY BETTER FOR EARLY STAGE HIGH RISK HISTOLOGIC TYPES OF ENDOMETRIAL CANCER**

ÇELİK E. G., AK N., SÖZEN H., SAİP P. M., TOPUZ S.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, vol.29, 2019 (SCI-Expanded)

- XXXIII. **Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: A multicentric Turkish Oncology Group (TOG) trial**

Saip P., Eralp Y., Sen F., Karaca H., ÖZKAN M., Cetin B., Benekli M., Kucukoner M., Isikdogan A., Un O., et al.

BREAST, vol.22, no.5, pp.628-633, 2013 (SCI-Expanded)

- XXXIV. **A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer**

Yildiz I., Tas F., Kilic L., Sen F., Saip P., Eralp Y., Keskin S., Karabulut S., Ciftci R., Serilmez M., et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.72, no.2, pp.437-444, 2013 (SCI-Expanded)

- XXXV. **Predictive Role of Midtreatment Changes in Survivin, GSTP1, and Topoisomerase 2 alpha Expressions for Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer**

Eralp Y., Keskin S., Akisik E. E., Akisik E., Igci A., Muslumanoglu M., Yilmaz S., Tunaci M., Camlica H., Tuzlali S., et al.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.36, no.3, pp.215-223, 2013 (SCI-Expanded)

- XXXVI. **Predictive Role of Midtreatment Changes in Survivin, GSTP1 and Topoisomerase 2a Expressions for Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer**

ERALP Y., KESKİN S., YÖRÜKER E. E., AKIŞIK E., İĞCİ A., MÜSLÜMANOĞLU M. E., Yılmaz S., TUNACI M., Çamlıca H., TUZLALI H. S., et al.

AMERICAN JOURNAL OF CLINICAL CLINICAL ONCOLOGY, vol.36, no.3, pp.215-223, 2013 (SCI-Expanded)

- XXXVII. **Triplet chemotherapy combination with cisplatin, gemcitabine and docetaxel in patients with chemotherapy-naïve advanced non-small cell lung cancer**

Tas F., Sen F., Guney N., Keskin S., Camlica H.

ONCOLOGY LETTERS, vol.5, no.5, pp.1699-1703, 2013 (SCI-Expanded)

- XXXVIII. **Evaluation of Glutathione S-Transferase P1 Polymorphisms (Ile105Val and Ala114Val) in Patients with Small Cell Lung Cancer**

Vural B., Yakar F., Derin D., Saip P., Yakar A., Demirkan A., Karabulut A., Ugurel E., Cine N., Kilicaslan Z., et al.

GENETIC TESTING AND MOLECULAR BIOMARKERS, vol.16, no.7, pp.701-706, 2012 (SCI-Expanded)

- XXXIX. **Phase II Study of Loading-Dose Ibandronate Treatment in Patients with Breast Cancer and Bone Metastases Suffering from Moderate to Severe Pain**

Altundag K., DİZDAR Ö., ÖZSARAN Z., ÖZKÖK S., Saip P., Eralp Y., Komurcu S., Kuzhan O., Ozguroglu M., Karahoca M.

ONKOLOGIE, vol.35, no.5, pp.254-258, 2012 (SCI-Expanded)

- XL. **Predictive Role of Midtreatment Changes in Survivin, GSTP1, and Topoisomerase 2? Expressions for Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer.**

Eralp Y., Keskin S., YÖRÜKER E. E., Yılmaz E. Z., İĞCİ A., MÜSLÜMANOĞLU M. E., Yılmaz S., TUNACI M., Çamlıca H., TUZLALI H. S., et al.

American Journal of Clinical Oncology, vol.20, pp.1-5, 2012 (SCI-Expanded)

- XLI. **Weekly docetaxel and cisplatin with concomitant radiotherapy in addition to surgery and/or consolidation chemotherapy in stage III non-small cell lung cancer**

Sen F., Saglam E. K., Toker A., Dilege S., Kizir A., Oral E. N., Saip P., Sakallioğlu B., Topuz E., Aydinler A.

CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.68, no.6, pp.1497-1505, 2011 (SCI-Expanded)

- XLII. **The access rate to diagnosis and treatment modalities in breast cancer patients in Turkey; Multicenter observational study**

Saip P., Keskin S., ÖZKAN M., Kaplan M. A., Aydogan F., Demirag G. G., Uzunoglu S., Engin H., Basaran G., Guler N., et al.

JOURNAL OF BUON, vol.16, no.4, pp.664-671, 2011 (SCI-Expanded)

- XLIII. **The role of antibiotic prophylaxis in totally implantable venous access device placement: results of a single-center prospective randomized trial**

- Karanlik H., Kurul S., Saip P., Unal E. S., Sen F., Disci R., Topuz E.
AMERICAN JOURNAL OF SURGERY, vol.202, no.1, pp.10-15, 2011 (SCI-Expanded)
- XLIV. **Glutathione S-transferase P1 polymorphisms are associated with time to tumor progression in small cell lung cancer patients**
Saip P., Sen F., Vural B., Ugurel E., Demirkan A., Derin D., Eralp Y., Camlica H., Ustuner Z., Ozbek U.
JOURNAL OF BUON, vol.16, no.2, pp.241-246, 2011 (SCI-Expanded)
- XLV. **Clinical and Pathological Features of Breast Cancer Associated with the Pathological Complete Response to Anthracycline-Based Neoadjuvant Chemotherapy**
Keskin S., Muslumanoglu M., Saip P., Karanlik H., Guveli M., Pehlivan E., Aydogan F., Eralp Y., Aydinler A., Yavuz E., et al.
ONCOLOGY, vol.81, no.1, pp.30-38, 2011 (SCI-Expanded)
- XLVI. **Mammaglobin and maspin transcripts in blood may reflect disease progression and the effect of therapy in breast cancer**
Bitişik Ö., SAİP P. M., Sağlam S., Derin D., DALAY M. N.
GENETICS MOLECULAR RESEARCH, vol.9, no.1, pp.97-106, 2010 (SCI-Expanded)
- XLVII. **Mammaglobin and maspin transcripts in blood may reflect disease progression and the effect of therapy in breast cancer**
Bitişik O., Saip P. M., Sağlam S., Derin D., Dalay N.
GENETICS AND MOLECULAR RESEARCH, vol.9, no.1, pp.97-106, 2010 (SCI-Expanded)
- XLVIII. **Yolk sac tumours of the ovary: Evaluation of clinicopathological features and prognostic factors**
Cicin I., Saip P., Guney N., Eralp Y., Ayan I., Kebudi R., Topuz E.
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, vol.146, no.2, pp.210-214, 2009 (SCI-Expanded)
- XLIX. **Identification of patients who may benefit from the prophylactic cranial radiotherapy among breast cancer patients with brain metastasis**
Saip P., Cicin I., Eralp Y., Karagol H., Kucucuk S., Alas R. C., Yavuz E., Dincer M., Sağlam E., Topuz E.
JOURNAL OF NEURO-ONCOLOGY, vol.93, no.2, pp.243-251, 2009 (SCI-Expanded)
- L. **Anti-Yo-associated cerebellar syndrome presenting with a brain mass**
Tuzun E., BEKTAS H. M., Icoz S., Kurtuncu M., SAİP P., Akman-Demir G.
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, no.2, pp.183-184, 2009 (SCI-Expanded)
- LI. **Malignant Ovarian Germ Cell Tumors A Single-Institution Experience**
Cicin I., Eralp Y., Saip P., Ayan I., Kebudi R., Iyibozkurt C., Tuzlali S., Gorgun O., Topuz E.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.32, no.2, pp.191-196, 2009 (SCI-Expanded)
- LII. **Factors related to recurrence after pathological complete response to postoperative chemotherapy in patients with epithelial ovarian cancer**
Karagol H., Saip P., Eralp Y., Topuz S., Berkman S., İlhan R., Topuz E.
TUMORI, vol.95, no.2, pp.207-211, 2009 (SCI-Expanded)
- LIII. **Effect of chemotherapy on the integrity of serum DNA in patients with breast cancer.**
GEZER U., ERALP Y., AKIŞIK E. E., Akışık E. Z., SAİP P. M., Topuz E., DALAY M. N.
Annals of Newyork Academy of Science, vol.1137, pp.175-179, 2008 (SCI-Expanded)
- LIV. **Size distribution of circulating cell-free DNA in sera of breast cancer patients in course of adjuvant chemotherapy**
GEZER U., ERALP Y., AKIŞIK E. E., Akışık E. Z., SAİP P. M., Topuz E., DALAY M. N.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, vol.46, pp.311-317, 2008 (SCI-Expanded)
- LV. **International Trends and Challenges in Breast Cancer as Perceived by Leaders in Medicine, Public Policy, and Advocacy**
Buchanan D., Coates A., Piccart M., Trudeau M., Saghir N., Forbes J., Kim S., Chen D. R., Chen S. C., Chang K. J., et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.31, no.5, pp.510, 2008 (SCI-Expanded)

- LVI. **Biweekly administration of gemcitabine and cisplatin chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer**
Tas F., Guney N., Derin D., Camlica H., Aydiner A., Topuz E.
INVESTIGATIONAL NEW DRUGS, vol.26, no.4, pp.363-368, 2008 (SCI-Expanded)
- LVII. **Effect of adjuvant chemotherapy on integrity of free serum DNA in patients with breast cancer**
GEZER U., Eralp Y., Yılmaz E. Z., YÖRÜKER E. E., SAİP P. M., Topuz E., DALAY M. N.
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol.1137, pp.175-9, 2008 (SCI-Expanded)
- LVIII. **Chemotherapy with pegylated liposomal doxorubicin and cisplatin in recurrent platinum-sensitive epithelial ovarian cancer**
Tas F., Derin D., Guney N., Aydiner A., Topuz E.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, vol.13, no.4, pp.330-334, 2008 (SCI-Expanded)
- LIX. **A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer**
Tas F., Guney N., Derin D., Aydiner A., Topuz E.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, vol.13, no.2, pp.156-160, 2008 (SCI-Expanded)
- LX. **TA T1 low and intermediate transitional cell carcinoma of the bladder: Recurrence rates and the timing of check cystoscopies within the first year**
Guney S., Guney N., Canogullari Z., Ergenekon E.
UROLOGIA INTERNATIONALIS, vol.80, no.2, pp.124-128, 2008 (SCI-Expanded)
- LXI. **Size distribution of circulating cell-free DNA in sera of breast cancer patients in the course of adjuvant chemotherapy**
Deligezer U., Eralp Y., Akisik E. E., Akisik E. Z., Saip P., Topuz E., Dalay N.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, vol.46, no.3, pp.311-317, 2008 (SCI-Expanded)
- LXII. **Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma**
Tas F., Derin D., Guney N., Camlica H., Aydiner A., Topuz E.
LUNG CANCER, vol.57, no.1, pp.79-83, 2007 (SCI-Expanded)
- LXIII. **The role of postoperative radiotherapy in node negative breast cancer patients with pT3-T4 disease**
Aksu G., Kucucuk S., Fayda M., Saynak M., Baskaya S., Saip P. M., Ozturk N., Aslay I.
EJSO, vol.33, no.3, pp.285-293, 2007 (SCI-Expanded)
- LXIV. **Malignant mesothelioma of the tunica vaginalis testis: a case report and review of the literature**
Guney N., Basaran M., Karayigit E., Muesluemanoglu A., Guney S., Kilicaslan I., Gulbarut S.
MEDICAL ONCOLOGY, vol.24, no.4, pp.449-452, 2007 (SCI-Expanded)
- LXV. **Primary non-Hodgkin's lymphoma of the rectum**
Guney N., Basaran M., Aksakalli N., Bavbek S., Erseven G.
ONKOLOGIE, vol.30, pp.385-387, 2007 (SCI-Expanded)
- LXVI. **Are CYP17 genotypes a biomarker for ovarian cancer in patients with cancer history in their family?**
Yazici H., TIGLI H., KADEHCI Z., Kucucuk S., Saip P., Issever H., OZCELIK H., Dalay N.
ONCOLOGY RESEARCH, vol.16, no.1, pp.43-47, 2006 (SCI-Expanded)
- LXVII. **Frequency of SOX group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters**
Vural B., Chen L., Saip P. M., Chen Y., Ustuner Z., Gonen M. S., Simpson A., Old L., Ozbek U., Gure A.
CANCER, vol.103, no.12, pp.2575-2583, 2005 (SCI-Expanded)
- LXVIII. **BRCA1 and BRCA2 mutations in Turkish familial and non-familial ovarian cancer patients: a high incidence of mutations in non-familial cases**
YAZICI ÖZBEK H., GLENDON G., YAZICI H., BURNIE S., SAİP P. M., BUYRU H. F., BENGİSU E., ANDRULIS I., DALAY M. N., ÖZÇELİK H.
HUMAN MUTATION, vol.20, no.1, pp.28-34, 2002 (SCI-Expanded)
- LXIX. **Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.**
Tas F., Aydiner A., Topuz E., YASASEVER V., Karadeniz A. N., Saip P. M.

Journal of experimental & clinical cancer research : CR, vol.19, no.4, pp.477-81, 2000 (SCI-Expanded)

- LXX. **BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients**
Yazici H., BITISIK O., AKISIK E., CABIOGLU N., SAIP P. M., MUSLUMANOGLU M. E., GLENDON G., BENGISU E., OZBILEN S., DINCER M., et al.
BRITISH JOURNAL OF CANCER, vol.83, no.6, pp.737-742, 2000 (SCI-Expanded)
- LXXI. **Celsite (R) port and catheter as an intraperitoneal access device in the treatment of ovarian cancer**
TOPUZ E., Salihoglu Y., AYDINER A., Saip P. M., TAS F., SOZEN T., BERKMAN S., BENGISU E.
JOURNAL OF SURGICAL ONCOLOGY, vol.74, no.3, pp.223-226, 2000 (SCI-Expanded)
- LXXII. **The role of chemotherapy in malignant mixed mullerian tumors of the female genital tract.**
TOPUZ E., ERALP Y., AYDINER A., Saip P. M., TAS F., YAVUZ E., Salihoglu Y.
ANNALS OF ONCOLOGY, vol.11, pp.87-88, 2000 (SCI-Expanded)
- LXXIII. **Correlations of serum CA125 level and computerized tomography (CT) imaging with laparotomic findings following intraperitoneal chemotherapy in patients with ovarian cancer.**
TOPUZ E., AYDINER A., Saip P. M., ERALP Y., TAS F., Salihoglu Y., TENEKECI N.
European journal of gynaecological oncology, vol.21, no.6, pp.599-602, 2000 (SCI-Expanded)
- LXXIV. **Long term results and prognostic factors of granulosa cell tumors of the ovary.**
SAIP P. M., Uygun K., Topuz E., BAŞARAN M., TAŞ F., AYDINER A., Aslay I., Dincer M.
ANNALS OF ONCOLOGY, vol.11, pp.87, 2000 (SCI-Expanded)
- LXXV. **Bcl-2 gene rearrangements and apoptosis rates in patients with non-Hodgkin's lymphoma during chemotherapy**
Yazici H., YALCINKAYA L., INANC S., ONAT H., SAIP P. M., DALAY N.
CLINICAL BIOCHEMISTRY, vol.32, no.1, pp.45-49, 1999 (SCI-Expanded)
- LXXVI. **Response evaluation of bone metastases in breast cancer: Value of magnetic resonance imaging**
SAIP P. M., TENEKECI N., AYDINER A., DINCER M., INANC S., DEMIR C., Oral E. N., TOPUZ E.
CANCER INVESTIGATION, vol.17, no.8, pp.575-580, 1999 (SCI-Expanded)
- LXXVII. **Prediction of radiological response of bone metastases to therapy by biochemical marker monitoring in patients with breast cancer: A preliminary study**
SAIP P. M., YASASEVER V., TENEKECI N., AYDINER A., INANC S., ONAT H., Disci R., TOPUZ E.
JOURNAL OF TUMOR MARKER ONCOLOGY, vol.13, no.3, pp.45-52, 1998 (SCI-Expanded)
- LXXVIII. **Investigation of the molecular changes during chemotherapy in non-Hodgkin's lymphoma**
Yazici H., SAIP P. M., INANC S., ONAT H., DALAY N.
RESEARCH COMMUNICATIONS IN MOLECULAR PATHOLOGY AND PHARMACOLOGY, vol.100, no.3, pp.301-311, 1998 (SCI-Expanded)
- LXXIX. **Catheter complications associated with intraperitoneal chemotherapy**
TOPUZ E., Saip P. M., AYDINER A., Salihoglu Y., YILMAZ T., TOPUZLU C.
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, vol.19, no.3, pp.275-279, 1998 (SCI-Expanded)
- LXXX. **Intraperitoneal cisplatin-mitoxantrone and intravenous ifosfamide combination as first-line treatment of ovarian cancer**
TOPUZ E., Saip P. M., Aydiner A., Salihoglu Y., BERKMAN S., BENGISU E.
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, vol.19, no.3, pp.265-270, 1998 (SCI-Expanded)
- LXXXI. **High dose epirubicin and cisplatin induction chemotherapy sequentially followed by ifosfamide and etoposide chemotherapy in extensive stage small cell lung cancer (ES-SCLC)**
DEMİRKAZIK A., Onat H., SAIP P. M., Ozguroglu M., Kars A., Cay F., Demir G., Uner A., Arpacı F., Aktan G.
ANNALS OF ONCOLOGY, vol.9, pp.105, 1998 (SCI-Expanded)
- LXXXII. **Cisplatin and epirubicin induction chemotherapy followed by chemoradiotherapy in limited stage small cell lung cancer (LS-SCLC)**
Cay F., Onat H., SAIP P. M., Kars A., DEMİRKAZIK A., AKBULUT H., Koca S., Akyol F., Aktan G., Firat D.
ANNALS OF ONCOLOGY, vol.9, pp.104, 1998 (SCI-Expanded)
- LXXXIII. **The effects of different treatment models on Turkish women with uterine sarcoma**
BERRAK E., ASLAY I., OZTURK N., DINCER M., AYDINER A., OZBILEN S., Disci R., SAIP P. M., TOPUZ E., TORE G. G.
EUROPEAN JOURNAL OF CANCER, vol.33, pp.943, 1997 (SCI-Expanded)

- LXXXIV. **Intraperitoneal cisplatin - mitoxantrone in ovarian cancer patients with minimal residual disease**
TOPUZ E., AYDINER A., SAIP P. M., BENGİSÜ E., BERKMAN S., Disci R.
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, vol.18, no.1, pp.71-75, 1997 (SCI-Expanded)

Articles Published in Other Journals

- I. **Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study**
FERHATOĞLU F., ÇAĞATAY T., OKUMUŞ G., AYDINER A., PAKSOY N., VATANSEVER S., AYDIN E., SAİP P.
Eurasian Journal of Medical Investigation, vol.7, no.2, pp.101-106, 2023 (Peer-Reviewed Journal)
- II. **Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors**
DOĞAN İ., KHANMAMMADOV N., PAKSOY N., VATANSEVER S., SAİP P., AYDINER A.
Eurasian Journal of Pulmonology, vol.25, no.1, pp.27-32, 2023 (Peer-Reviewed Journal)
- III. **Prognostic Factors Influencing Progression-Free Survival in HER2-Positive Metastatic Breast Cancer Patients Who Were Treated with A Combination of Lapatinib and Capecitabine**
DOĞAN İ., Paksoy N., AK N., VATANSEVER S., Saip P., AYDINER A.
European Journal of Breast Health, vol.19, no.2, pp.128-133, 2023 (Scopus)
- IV. **Comparison of Clinical, Pathological, and Prognostic Features in BRCA Mutant and Wild-Type Male Breast Cancer Patients**
DOĞAN İ., Aydin E., Yazici H., Saip P.
EUROPEAN JOURNAL OF BREAST HEALTH, vol.18, no.4, pp.323-328, 2022 (ESCI)
- V. **Outcomes and Prognostic Factors in Patients with EGFR Mutant Metastatic Non-Small Cell Lung Cancer Who Treated with Erlotinib**
DOĞAN İ., Khanmammadov N., Ahmed M. A., Yildiz A., Saip P., Aydiner A., VATANSEVER S.
CLINICAL CANCER INVESTIGATION JOURNAL, no.4, pp.5-9, 2022 (ESCI)
- VI. **Crizotinib in Metastatic ALK mutant Non-small Cell Lung Cancer Patients: A Single Centre Experience**
DOĞAN İ., Khanmammadov N., Ahmed M. A., Yildiz A., Saip P., Aydiner A., VATANSEVER S.
CLINICAL CANCER INVESTIGATION JOURNAL, no.3, pp.25-29, 2022 (ESCI)
- VII. **Henna Application in the Prevention of Capecitabine-Induced Hand-Foot Syndrome in Breast and Colorectal Cancer Patients**
KAYIKÇI E. E., CAN G., Sen F., Saip P.
FLORENCE NIGHTINGALE JOURNAL OF NURSING-FLORENCE NIGHTINGALE HEMSİRELİK DERGİSİ, vol.28, no.3, pp.299-311, 2020 (ESCI)
- VIII. **Cost effectiveness of breast cancer screening in Turkey, a developing country: Results from Bahçeşehir Mammography screening project**
ÖZMEN V., ÖZKAN GÜRDAL S., CABIOĞLU N., ÖZÇINAR B., ÖZAYDIN A. N., KAYHAN A., ARIBAL M. E., SAİP P. M.
European Journal of Breast Health, 2017 (ESCI)
- IX. **Analysis of circulating microRNAs during adjuvant chemotherapy in patients with luminal A breast cancer**
YÖRÜKER E. E., Aydoğan F., GEZER U., SAİP P. M., Dalay M. N.
MOLECULAR AND CLINICAL ONCOLOGY, vol.3, pp.954-958, 2015 (ESCI)
- X. **Analysis of circulating microRNAs during adjuvant chemotherapy in patients with luminal A breast cancer.**
YÖRÜKER E. E., AYDOĞAN F., GEZER U., SAİP P. M., DALAY N.
Mol Clin Oncol, vol.3, no.4, pp.954-958, 2015 (Peer-Reviewed Journal)
- XI. **The Outcome of Patients with Triple Negative Breast Cancer: The Turkish Oncology Group Experience**
Eralp Y., Kilic L., Alco G., BAŞARAN G., Dogan M., Dincol D., Demirci S., Icli F., Onur H., SAİP P. M., et al.
JOURNAL OF BREAST HEALTH, vol.10, no.4, pp.209-215, 2014 (ESCI)
- XII. **Endometrium Kanserinde Kemoterapi**

KARABULUT S., SAİP P. M.

Türkiye Klinikleri Jinekoloji Obstetrik, vol.7, no.3, pp.100-106, 2014 (Peer-Reviewed Journal)

XIII. The Frequencies of Breast Cancer BC in Extreme Ages Changing Over Time

KESKİN S., ÇİFTÇİ R., KARABULUT S., KÜÇÜÇÜK S., YILDIZ İ., KILIÇ L., ERALP Y., SAİP P. M.

Mediterranean Oncology Journal, vol.1, pp.46-19, 2012 (Peer-Reviewed Journal)

XIV. LOCALLY ADVANCED BREAST CANCER-2010 ISTANBUL BREAST CANCER CONSENSUS MEETING

Guler N., Karabulut B., KOÇDOR M. A., KAYA H., Esen G., Ozaslan C., SAİP P. M., GÖRKEN İ.

JOURNAL OF BREAST HEALTH, vol.7, no.2, pp.68-89, 2011 (ESCI)

XV. Extended latissimus dorsi myocutaneous flap for breast reconstruction: analysis of 30 patients

Kurul S., KARANLIK H., SAİP P. M., Kucucuk S., Aslay I.

TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, vol.26, no.4, pp.149-156, 2011 (ESCI)

XVI. Inflammatory breast cancer

Keskin S., SAİP P. M.

TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, vol.26, no.2, pp.94-99, 2011 (ESCI)

XVII. CYP1A1, GSTM1 and NQO1 gene polymorphisms: Genetic risk factors for small cell lung cancer

demirkan a., VURAL B., üstüner z., uygun k., öztürk açıklan b., derin d., SAİP P. M., ÖZBEK U.

TURKISH JOURNAL OF CANCER, vol.35, pp.171-176, 2005 (Peer-Reviewed Journal)

XVIII. ANTIEMETIC EFFICACY OF DIAZEPAM IN THE PROPHYLAXIS OF ACUTE AND DELAYED EMESIS INDUCED BY CISPLATIN BASED CHEMOTHERAPY TREATED WITH STANDARD ANTI EMETICS

SAİP P. M., Onat H., Uygun K., Demir C., Salepci T., Guney N., BAŞARAN M., Topuz E.

TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, vol.20, no.2, pp.67-72, 2005 (ESCI)

Books & Book Chapters

I. An approach to medical and clinical pharmacology clinical research practices at Capa Campus: A Good Clinical Practices (GCP) training model.

Demir M., Dizdar M. Y., Bebek N., Akkaya V. A., Tükek T., Gürol A. O., Saip P. M.

Peertechz publication, California, 2020

Refereed Congress / Symposium Publications in Proceedings

I. Comparison of bevacizumab plus doublet chemotherapy regimens in patients with metastatic or recurrent ovarian cancer.

Khanmammadov N., DOĞAN İ., Saip P., Aydinler A.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 2 - 06 June 2023

II. Outcomes and prognostic factors in patients with HER2-positive metastatic breast cancer with brain metastasis

Dogan I., Kızıldağ Yırgın İ., Özkurt S., İbiş K., Vatansever S., Saip P. M., Aydinler A.

2022 ASCO Annual Meeting , Illinois, United States Of America, 3 - 07 June 2022, pp.14002

III. Predictors of osimertinib response at second-line treatment in EGFR mutant non-small cell lung cancer patients with acquired T790M resistance mutation

Dogan I., Gurbuz M., Paksoy N., Khanmamadov N., Vatansever S., Saip P., Demirkazik A., Aydinler A.

Molecular Analysis for Precision Oncology Virtual Congress, ELECTR NETWORK, 7 - 09 October 2021, vol.32

IV. Evaluation of the relationship between clinicopathological features at diagnosis and acquisition of T790M resistance mutation in patients with EGFR-mutant metastatic lung cancer

Dogan I., Khanmamadov N., Paksoy N., Vatansever S., Saip P., Aydinler A.

Molecular Analysis for Precision Oncology Virtual Congress, ELECTR NETWORK, 7 - 09 October 2021, vol.32

V. Clinicopathologic features and prognostic factors in male breast cancer: A single centre experience

DOĞAN İ., AYDIN E. M., AK N., İBİŞ K., Sukruoglu Ö., Erciyas S., YAZICI H., AYDINER A., SAİP P. M.

ESMO Asia Virtual Congress, ELECTR NETWORK, 20 - 22 November 2020, vol.31

- VI. **OVER KANSERLERİNDE MİR-1260 MİKORNA AİLESİNİN ARAŞTIRILMASI**
Adamnejad Ghafour A., Akdeniz Ödemiş D., Avşar M., Tunçer Ş. B., Şükrüoğlu Erdoğan Ö., Kılıç Erciyas S., Kurt B., Çelik B., Türkcan G. K., Saip P. M., et al.
2. Temel Onkoloji Sempozyumu, Ankara, Turkey, 16 - 18 October 2019, pp.42
- VII. **OVER KANSERLİ HASTALARDA MİR-16-5P, MİR-17-5P VE MİR-638 EKSPRESYON DÜZEYLERİNİN ARAŞTIRILMASI**
Avsar Sarali M., Tunçer Ş. B., Akdeniz Ödemiş D., Kılıç Erciyas S., Şükrüoğlu Erdoğan Ö., Çelik B., Türkcan G. K., Adamnejad Ghafour A., Kurt B., Saip P. M., et al.
2. Temel Onkoloji Sempozyumu, Ankara, Turkey, 16 - 18 October 2019, pp.32
- VIII. **AİLESEL VE SPORADİK OVER KANSERLİ HASTALARDA MİR-423-5P VE MİR- 664B-5P'NİN EKSPRESYON DÜZEYLERİNİN ARAŞTIRILMASI**
Kurt B., Avşar M., Tunçer Ş. B., Adamnejad Ghafour A., Türkcan G. K., Kılıç Erciyas S., Şükrüoğlu Erdoğan Ö., Akdeniz Ödemiş D., Çelik B., Saip P. M., et al.
2. Temel Onkoloji Sempozyumu, Ankara, Turkey, 16 - 18 October 2019, pp.41
- IX. **The Investigation of Expression Levels of miR 16-5p, miR-17-5p, miR-638 in Patients With Ovarian Cancer**
avşar m., AKDENİZ ÖDEMİŞ D., TUNÇER Ş. B., kurt b., Adamnejad Ghafour a., kuru türkcan g., KILIÇ ERCİYAS S., ŞÜKRÜOĞLU ERDOĞAN Ö., ÇELİK B., SAİP P. M., et al.
2. International cancer and ion channel congress, İzmir, Turkey, 22 - 24 September 2019, pp.43
- X. **İyi Klinik Uygulamalar Çerçevesinde Klinik Araştırma Eğitim Değerlendirmesi: İstanbul Tıp Fakültesi Tıbbi ve Klinik Farmakoloji Uygulamaları (INSAC-18-1112)(ISBN: 978-605-69062-0-6)**
DEMİR M., DİZDAR M. Y., BEBEK N., AKKAYA V. A., TÜKEK T., GÜRSER R. C., GÜROL A. O., SAİP P. M., ÜRESİN A. Y.
International Science and Academic Congress'18, Konya, Turkey, 8 - 09 December 2018, vol.1, pp.99-103
- XI. **BRCA1 İLİŞKLİ OVER KANSERİNDE YÜKSEK EKSPRESYON DÜZEYİ GÖSTEREN MİRNA'LAR**
TUNÇER Ş. B., ÇELİK B., KURU G., KILIÇ ERCİYAS S., ŞÜKRÜOĞLU ERDOĞAN Ö., AKDENİZ ÖDEMİŞ D., AVSAR M., SAİP P. M., YAZICI H.
1. TEMEL ONKOLOJİ SEMPOZYUMU, İzmir, Turkey, 9 - 11 May 2018, no.5, pp.43
- XII. **YÜKSEK RİSKLİ MEME VE YUMURTALIK KANSERİNDE BRCA1 VE BRCA2 GENLERİNDE BULUNAN BÜYÜK DELESYON VE DUPLİKASYONLARIN FREKANSI**
AVSAR M., KILIÇ ERCİYAS S., ŞÜKRÜOĞLU ERDOĞAN Ö., TUNÇER Ş. B., AKDENİZ ÖDEMİŞ D., KURU G., ÇELİK B., SAİP P. M., YAZICI H.
1. TEMEL ONKOLOJİ SEMPOZYUMU, İzmir, Turkey, 9 - 11 May 2018, no.2, pp.40
- XIII. **AİLESEL OVER KANSERİNE YATKINLIĞI BELİRLEMEDE KULLANILABİLECEK MİRNA'LAR**
TUNÇER Ş. B., KURU G., KILIÇ ERCİYAS S., ÇELİK B., AKDENİZ ÖDEMİŞ D., ŞÜKRÜOĞLU ERDOĞAN Ö., AVSAR M., SAİP P. M., YAZICI H.
1. TEMEL ONKOLOJİ SEMPOZYUMU, İzmir, Turkey, 9 - 11 May 2018, no.6, pp.44
- XIV. **miRNAs leading to increase susceptibility of hereditary ovarian cancer**
ÇELİK B., KURU G., TUNÇER Ş. B., KILIÇ S., ŞÜKRÜOĞLU Ö., AKDENİZ ÖDEMİŞ D., AVSAR M., SAİP P. M., YAZICI H.
Joint Meeting on 4th World Congress on Human Genetics & Genetic Diseases and 3rd International Conference on Molecular Medicine & Diagnostics, Dubai, United Arab Emirates, 19 - 20 April 2018, vol.12, pp.85
- XV. **The high expression levels of miRNAs in BRCA1 related hereditary ovarian cancer**
ÇELİK B., KURU G., TUNÇER Ş. B., KILIÇ S., ŞÜKRÜOĞLU ERDOĞAN Ö., AKDENİZ ÖDEMİŞ D., AVSAR M., SAİP P. M., YAZICI H.
Joint Meeting on 4th World Congress on Human Genetics & Genetic Diseases and 3rd International Conference on Molecular Medicine & Diagnostics, Dubai, United Arab Emirates, 19 - 20 April 2018, vol.12, pp.84
- XVI. **Frequency of rearrangements versus small indels mutations in BRCA1 and BRCA2 genes in Turkishspace patients with high risk breast and ovarian cancer**
Çelik B., Kuru G., Tunçer Ş. B., Kılıç S., Şükrüoğlu Erdoğan Ö., Avsar M., Akdeniz Ödemiş D., Saip P. M., Yazıcı H.
Joint Meeting on 4th World Congress on Human Genetics & Genetic Diseases and 3rd International Conference on

Molecular Medicine & Diagnostics, Dubai, United Arab Emirates, 19 - 20 April 2018, vol.12, pp.86

- XVII. **miRNAs leading to increase susceptibility of hereditary ovarian cancer**
Çelik B., Türkcan G. K., Tunçer Ş. B., Kılıç Erciyas S., Şükrüoğlu Erdoğan Ö., Akdeniz Ödemiş D., Avsar Saral M., Saip P. M., Yazıcı H.
4th World Congress on Human Genetics & Genetic Diseases and 3rd International Conference on Molecular Medicine & Diagnostics, Dubai, United Arab Emirates, 19 - 20 April 2018, vol.12, pp.85
- XVIII. **FREQUENCY OF BRCA1 AND BRCA2 MUTATIONS IN PATIENTS WITH UNSELECTED TRIPLE-NEGATIVE BREAST CANCER**
Avşar M., TUNÇER Ş. B., SAİP P. M., YAZICI H.
VI. International Congress of Molecular Medicine, İstanbul, Turkey, 22 May - 25 September 2017, pp.282
- XIX. **Serviks kanserinde nadir rastlanan metastaz bölgesi: İskiyorektal fossa**
İBİŞ K., KÜÇÜCÜK N. S., ŞANLI Y., KARTAL M. G., SARI M., SÖZEN H., YAVUZ E., SAİP P. M.
22. Ulusal Kanser Kongresi, Turkey, 19 - 23 April 2017
- XX. **Over Kanserinde HMGB1 ve IRE1'in Önemi**
BİLGİN DOĞRU E., TİLGİN YASASEVER C., SERİLMEZ M., SAİP P. M., YASASEVER F. V.
22. Ulusal Kanser Kongresi, Antalya, Turkey, 19 - 23 April 2017, pp.159
- XXI. **Regional Distribution And Frequency Of Brca1 And Brca2 Gene Mutations In Turkish Population Including Balkan Turks**
AVŞAR M., AKDENİZ ÖDEMİŞ D., KILIÇ S., TUNÇER Ş. B., ŞÜKRÜOĞLU ERDOĞAN Ö., KURU G., ALTUNDAĞ K., SAİP P. M., YAZICI H.
International Breastanbul Conference, İstanbul, Turkey, 10 - 12 November 2016, pp.51
- XXII. **Frequency of Large Deletions and Duplications in the BRCA1/2 Genes in Turkish High Risk Breast and Ovarian Cancer Cases**
AKDENİZ ÖDEMİŞ D., ŞÜKRÜOĞLU ERDOĞAN Ö., KILIÇ S., TUNÇER Ş. B., AVŞAR M., KURU G., ALTUNDAĞ K., KILIÇ L., ÇİFTÇİ R., KARABULUT S., et al.
International Breastanbul Conference, İstanbul, Turkey, 10 - 12 November 2016, pp.7
- XXIII. **Frequency of ER,PR,HER2 and Triple Negative Hormone Receptors in BRCA1/BRCA2 Gene Mutation Positive Breast Cancer Cases**
TUNÇER Ş. B., KILIÇ S., AKDENİZ ÖDEMİŞ D., ŞÜKRÜOĞLU ERDOĞAN Ö., AVŞAR M., KURU G., SAİP P. M., YAZICI H., KÜÇÜCÜK N. S.
International Breastanbul Conference, İstanbul, Turkey, 10 - 12 November 2016, pp.60
- XXIV. **BRCA1 AND BRCA2 GENE MUTATION FREQUENCY OF HIGH RISK OVARIAN CANCER CASES IN TURKISH POPULATION INCLUDING BALKAN TURKS**
KURU G., AKDENİZ ÖDEMİŞ D., KILIÇ S., TUNÇER Ş. B., ŞÜKRÜOĞLU ERDOĞAN Ö., AVŞAR M., ALTUNDAĞ K., SAİP P. M., YAZICI H.
ESGO 2016: Prevention in gynaecological malignancies, Antalya, Turkey, 8 - 10 September 2016, pp.2
- XXV. **REGIONAL DISTRIBUTIONS of BRCA1 AND BRCA2 GENE MUTATIONS IN TURKISH HEREDITARY OVARIAN CANCER PATIENTS INCLUDING BALKAN TURKS**
KILIÇ S., KURU G., AKDENİZ ÖDEMİŞ D., TUNÇER Ş. B., ŞÜKRÜOĞLU ERDOĞAN Ö., AVŞAR M., ALTUNDAĞ K., SAİP P. M., YAZICI H.
ESGO 2016: Prevention in gynaecological malignancies, Antalya, Turkey, 8 - 10 September 2016, pp.1
- XXVI. **Panel Gene Testing For High Risk Early Age Breast Cancer Patients in Turkey**
ŞÜKRÜOĞLU ERDOĞAN Ö., KILIÇ S., TUNÇER Ş. B., AKDENİZ ÖDEMİŞ D., AVŞAR M., KURU G., SAİP P. M., YAZICI H.
The 43rd ISOBM Annual Congress, Chicago, United States Of America, 1 - 06 September 2016, no.211, pp.55
- XXVII. **WHOLE GENOME EXPRESSION LEVELS OF miRNA IN HIV NEGATIVE KAPOSI'S SARCOMA**
TUNÇER Ş. B., AKDENİZ ÖDEMİŞ D., KILIÇ S., Avşar M., ŞÜKRÜOĞLU ERDOĞAN Ö., Kuru G., SAİP P. M., ŞEN F., YAZICI H.
The 43rd ISOBM Annual Congress, Chicago, United States Of America, 1 - 06 September 2016, no.212, pp.56
- XXVIII. **Novel miRNAs in HIV Negative Kaposi's Sarcoma Patients**
TUNÇER Ş. B., AKDENİZ ÖDEMİŞ D., AVŞAR M., KILIÇ S., ŞÜKRÜOĞLU ERDOĞAN Ö., KURU G., SAİP P. M., ŞEN F., YAZICI H.

The 43rd ISOBM Annual Congress, Chicago, United States Of America, 1 - 06 September 2016, no.210, pp.54

- XXIX. **KAPOİ SARKOMUNDA GENOM DÜZEYİNDE MİRNA EKSPRESYONLARININ ARAŞTIRILMASI**
TUNÇER Ş. B., AKDENİZ ÖDEMİŞ D., KILIÇ S., AVŞAR M., ŞÜKRÜOĞLU ERDOĞAN Ö., KURU G., SAİP P. M., KURUL S., ŞEN F., YAZICI H.
6.Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 23 - 27 March 2016, no.241, pp.505
- XXX. **KSHV POZİTİF VE KSHV NEGATİF KAPOİ SARKOMLU HASTALARIN ETİYOLOJİSİNDE YENİ MİRNA'LARIN SAPTANMASI**
TUNÇER Ş. B., AKDENİZ ÖDEMİŞ D., KILIÇ S., AVŞAR M., ŞÜKRÜOĞLU ERDOĞAN Ö., KURU G., SAİP P. M., KURUL S., ŞEN F., YAZICI H.
6.Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 23 - 27 March 2016, no.245, pp.508
- XXXI. **YÜKSEK RİSKLİ TÜRK MEME KANSERLİ HASTALARDA BRCA1 VE BRCA2 GENLERİNDE GÖRÜLEN SNP/VUS'LARIN DAĞILIMI**
KILIÇ S., AVŞAR M., TUNÇER Ş. B., ŞÜKRÜOĞLU ERDOĞAN Ö., AKDENİZ ÖDEMİŞ D., KURU G., SAİP P. M., YAZICI H.
6.Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 23 - 27 March 2016, no.246, pp.509
- XXXII. **ERKEN YAŞ MEME KANSER HASTALARINDA ÇOKLU GEN ANALİZİ**
ŞÜKRÜOĞLU ERDOĞAN Ö., KILIÇ S., AVŞAR M., AKDENİZ ÖDEMİŞ D., TUNÇER Ş. B., KURU G., SAİP P. M., YAZICI H.
6.Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 23 - 27 March 2016, no.31, pp.238
- XXXIII. **Clinical and pathologic characteristics of ovarian cancer patients with BRCA1 and BRCA2 mutations in Turkish population**
Saip P. M., Akdeniz B., Tuncer B., Kilic S., Sukruoglu O., Altundag K., Ciftci R., Yazici H.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32
- XXXIV. **Aksiller metastazı bulunan hangi hastalarda neoadjuvan kemoterapi sonrasında aksiller diseksiyon yapılmayabilir?**
KARANLIK H., ÖZGÜR İ., FAYDA E. M., YAVUZ E., MUDUN A., SAIP P., ERALP Y., KURUL S.
19. Ulusal Cerrahi Kongresi, Antalya, Turkey, 16 - 20 April 2014
- XXXV. **Epitelyal Over Kanserinin Belirlenmesi Üzerinde Protease Activated Receptor-1(PAR-1) Düzeylerinin Herhangi Bir Tanısal Değeri Var Mıdır?**
Karabulut S., Ciftci R., Vatansever S., TAŞ F., TILGEN YASASEVER C., YASASEVER F. V., Aydinler A., SAİP P. M.
5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.421
- XXXVI. **KALITSAL MEME KANSER HASTALARINDA SAPTANAN BRCA1/2 GEN MUTASYONLARININ BÖLGESEL VE ETNİK DAĞILIMI İLE KLİNİK ÖZELLİKLERİ**
AKDENİZ ÖDEMİŞ D., TUNÇER Ş. B., KILIÇ S., ŞÜKRÜOĞLU Ö., ALTUNDAĞ K., KILIÇ I., ÇİFTÇİ R., ÖZEL YILDIZ S., KARABULUT S., EKENEL M., et al.
5. türk tıbbi onkoloji kongresi, Antalya, Turkey, 19 - 23 March 2014
- XXXVII. **Serum Transforme Edici Büyüme Faktörü-Beta1 (TGF-B1) Seviyelerinin Epitelyal Over Kanserli Hastalarda Klinik Önemi**
Karabulut S., Ciftci R., Tastekin D., VATANSEVER S., TAŞ F., TILGEN YASASEVER C., DURANYILDIZ H. D., Aydinler A., SAİP P. M.
5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.421
- XXXVIII. **Serum Hücresel Adhezyon Molekülleri (VCAM-1, EPCAM) Seviyelerinin Meme Kanserli Hastalarda Tanısal, Prediktif ve Prognostik Rolü**
Karabulut S., Ciftci R., Tastekin D., VATANSEVER S., Aydinler A., TILGEN YASASEVER C., Duranyildiz D., SAİP P. M.
5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.493
- XXXIX. **Serum Makrofaj Migrasyon İnhibitör Faktörü (MIF) Düzeylerinin Epitelyal Over Kanserli Hastalarda Tanısal, Prediktif ve Prognostik Rolü**
Karabulut S., Ciftci R., Tastekin D., Vatansever S., Keskin S., Yildiz I., TILGEN YASASEVER C., Duranyildiz D., Aydinler A., SAİP P. M., et al.
5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.420
- XL. **Epitelyal Over Kanserli Hastalarda Yüksek Serum Epidermal Büyüme Faktör Reseptörü (EGFR) Düzeyleri Kötü Progresyonsuz Sağkalımla İlişkilidir**

Karabulut S., Ciftci R., Tastekin D., TİLGEN YASASEVER C., VATANSEVER S., Duranyildiz D., TAŞ F., Aydiner A., SAİP P. M.

5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.428

- XLII. **2008-2012 Yılları Arasında Kanser Genetiği Polikliniğine Başvuran Yüksek Riskli Meme/Over Kanser Sendromlu Vakalarının Dağılımı**
AKDENİZ ÖDEMİŞ D., TUNÇER Ş. B., altundağ k., şükrüoğlu ö., kılıç S., kılıç I., SAİP P. M., DALAY M. N., YAZICI H.
20. ULUSAL KANSER KONGRESİ, Antalya, Turkey, 19 - 23 April 2013
- XLIII. **The effect of contaminant chemoradiation on disease control and survival in servix carsinoma**
Aslay I., KÜÇÜCÜK N. S., SAİP P. M., ERALP Y., KEMİKLER G., Özbay İ., Seraslan B., OKUTAN M.
ESRTO 31, 9 - 13 May 2012, vol.103, pp.275
- XLIII. **The predictive role of midtreatment changes in survivin, GSTP1 and Topoisomerase 2 alpha expressions for pathologic complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer**
Keskin S., Eralp Y., Yılmaz E. Z., YÖRÜKER E. E., İĞCİ A., MÜSLÜMANOĞLU M. E., Yılmaz S., TUNACI M., Çamlıca H., TUZLALI H. S., et al.
2011 ASCO Annual Meeting, United States Of America, 1 - 04 June 2011, pp.10539
- XLIV. **The changing pattern of risk factors and disease characteristics of breast cancer in Turkey:Across-sectional study of a Turkish oncology group(BREASTTURK)**
SAİP P. M.
JOURNAL OF CLINICAL ONCOLOGY, Alexandria, United States Of America, 20 May 2011, vol.29, no.15
- XLV. **The impact of 21 gene recurrence score (RS)scores on treatment decisions:Retrospective evaluation in Turkish early-stage breast cancer(BC)patients**
SAİP P. M.
JOURNAL OF CLINICAL ONCOLOGY, Alexandria, United States Of America, 20 May 2011, vol.29, no.5
- XLVI. **Phase II study of lapatinib in combination with vinorelbine in patients with ErbB2-amplified recurrent or metastatic breast cancer**
SAİP P. M.
JOURNAL OF CLINICAL ONCOLOGY, Alexandria, United States Of America, 20 May 2011, vol.29, no.15
- XLVII. **Nine versus52 weeks of adjuvant trastuzumab in early breast cancer:An observational study of the Turkish Oncology Group**
SAİP P. M.
JOURNAL OF CLINICAL ONCOLOGY, Alexandria, United States Of America, 20 May 2011, vol.29, no.15, pp.629
- XLVIII. **Phase II study of loading-dose ibandronate treatment in patients in breast cancer and bone metastases suffering from moderate to severe pain**
SAİP P. M.
JOURNAL OF CLINICAL ONCOLOGY, Alexandria, United States Of America, 20 May 2010, vol.28, no.15
- XLIX. **Association between glutathione s-transferase P1 polymorphisms and time to tumor progression in small cell lung cancer patients**
SAİP P. M.
JOURNAL OF CLINICAL ONCOLOGY, Alexandria, United States Of America, 20 May 2010, vol.28, no.15
- L. **The future of breast cancer research and practice in Asia, Latin America, and the Middle East/North Africa: a qualitative horizon scanning analysis.**
SAİP P. M.
31st Annual San Antonio Breast Cancer Symposium, Philadelphia, United States Of America, 15 January 2009, vol.69, no.2, pp.328-329
- LI. **Size distribution o circulating cell-free DNA in sera of breast cancer aptients in course of adjuvant therapy**
GEZER U., ERALP Y., AKIŞIK E. E., Akışık E. Z., SAİP P. M., Topuz E., DALAY M. N.
Symposium on Circulating Nucleic Acids in Plasma Serum-V, Russia, 1 - 04 August 2007, pp.9
- LII. **Size Distrubution Circulating Cell-Free DNA In Sera of Breast Cancer Patients In Course of Adjuvant Therapy**

GEZER U., Eralp Y., YÖRÜKER E. E., Yılmaz E. Z., SAİP P. M., Topuz E., DALAY M. N.

Symposium on Circulating Nucleic Acids in Plasma/Serum -V, Russia, 1 - 04 August 2007, pp.9

LIII. Factors related with recurrence after complete pathologic response to post- operative chemotherapy in patients with epithelial ovarian cancer

Karagol H., SAİP P. M., Uygun K., Eralp Y., TOPUZ S., Berkman S., Ilhan R., Topuz E.

31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.174

LIV. Serum Her2 extracellular domain (ECD) levels, pAkt and pMAPK expressions as potential markers for response to trastuzumab(T)-based therapy in metastatic breast cancer (MBC) patients (PTS). A Turkish oncology group study

Basaran G. A., Guney N., Saip P., Iyikesici S., Kaya H., Yazici H., Serdar T. N.

31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.90-91

LV. Induction chemotherapy followed by chemoradiotherapy in patients with stage IIIA-B non-small cell lung cancer (NSCLC)

DAĞOĞLU SAKİN R. N., AYDINER A., Sakallioğlu B., Oztürk B., Eralp Y., SAİP P. M., ORAL E. N., KIZIR A., Topuz E.

31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.229

LVI. Detection of circulating breast cancer cells in relation to therapy.

Bitisik O., SAİP P. M., Sağlam S., Dalay N.

41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 13 - 17 May 2005, vol.23

LVII. Immunoreactivity to SOX-1,-2,-3 and ZIC2 antigens and correlation to survival in small cell lung cancer (SCLC).

Chen L., Vural B., Ustuner Z., SAİP P. M., ÖZBEK U., Gonen M., Old L., Chen Y., Gure A.

40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22

LVIII. Oral etoposide in patients (pts) with Kaposi's sarcoma (KS)

AYDINER A., TAS F., SAİP P. M., KARADENİZ A. N., DEMİR C., SALEPÇİ T., TOPUZ E.

EUROPEAN JOURNAL OF CANCER, Oxford, United Kingdom, 01 September 1997, vol.33, no.8, pp.1178

LIX. Oral etoposide in patients with small cell lung cancer

TOPUZ E., TAŞ F., AYDINER A., DEMİR C., SAİP P. M., SALEPÇİ T., KARADENİZ A. N., ERTÜRK N.

EUROPEAN JOURNAL OF CANCER, Oxford, United Kingdom, 01 September 1997, vol.33, no.8, pp.1072

LX. Küçük hücreli dışı, akciğer kanserlerinde palyatif tedavide radyoterapi sonrası kemoterapinin yeri

SAİP P. M., ALGÜR E., KARADENİZ A., ORAL E., ALTUN M., DİNÇER M., TOPUZ E.

I. Ulusal Radyasyon Onkolojisi Kongresi, İzmir, Turkey, 16 - 18 May 1994, pp.1563

Supported Projects

CABIOĞLU N., ÖNER G., ÖNDER S., SAİP P. M., Project Supported by Higher Education Institutions, Neoadjuvan

Kemoterapi Gören Lokal İleri Meme Kanseri Hastalarında İmmünolojik Parametrelerin ve Kemokin Reseptör

Ekspresyonunun Prediktif ve Prognostik Önemi, 2017 - Continues

TUNÇER Ş. B., ŞÜKRÜOĞLU ERDOĞAN Ö., ÇELİK B., KILIÇ ERCİYAS S., YAZICI H., AKDENİZ ÖDEMİŞ D., SAİP P. M., GÜNGÖR

UĞURLUCAN F., Project Supported by Higher Education Institutions, Over Kanseri Metilasyon Profilinin Araştırılması, 2020 - 2024

Saip P. M., Şeker M., Göker E., Şanlı U. A., Özgüroğlu M., Demirelli F. H., Oğuz A., Özyılkan Ö., Project Supported by Private

Organizations in Other Countries, DAHA ÖNCE TEDAVİ EDİLMEMİŞ EPİTELİYAL OVER KANSERİ HASTALARINDA

AVELUMAB'IN (MSB0010718C) KEMORERAPİ İLE BİRLİKTE VE/VEYA KEMOTERAPİ SONRASINDA ETKİLİLİĞİNİ VE

GÜVENLİLİĞİNİ DEĞERLENDİREN RANDOMİZE, AÇIK ETİKETLİ, ÇOK MERKEZLİ BİR FAZ 3 ÇALIŞMA, 2019 - 2020

Saip P. M., Yalçın B., Çiçin İ., Gümüş M., Çubukçu E., Project Supported by Private Organizations in Other Countries, DAHA

ÖNCE TEDAVİ EDİLMEMİŞ, OPERE EDİLEMEYEN LOKAL İLERİ VEYA METASTATİK ÜÇLÜ NEGATİF MEME KANSERİ OLAN HASTALARDA PAKLİTAKSEL İLE PLASEBOYA KARŞI PAKLİTAKSEL İLE KOMBİNASYON HALİNDE ATEZOLİZUMAB (ANTİPDL1 ANTİKORU) İLE İLGİLİ BİR FAZ 3, ÇOK MERKEZLİ ÇİFT KÖR PLASEBO KONTROLLÜ ÇALIŞMA, 2018 - 2020

Saip P. M., Taşkiran Ç., Akbulut H., Ayhan A., Arvas M. M., Project Supported by Private Organizations in Other Countries, Yeni Tanı Almış Evre 3 veya Evre 4 Over, Fallop Tüpü veya Primer Peritoneal Kanseri Hastalarda Atezolizumabin Plaseboya Karşı Paklitaksel, Karboplatin ve Bevasizumabla Kombinasyon Halinde Uygulanmasında Yönelik Faz 3, Çok Merkezli, Randomize Çalışma, 2017 - 2019

YAZICI H., TUNÇER Ş. B., SAİP P. M., Project Supported by Higher Education Institutions, Over Kanseri Aile Bireylerinde tüm genom miRNA moleküllerinin Araştırılması, 2016 - 2017

Saip P. M., Project Supported by Private Organizations in Other Countries, DAHA ÖNCE anti-HER2 VE KEMOTERAPİ BAZLI TEDAVİ ALMIŞ, HER2 POZİTİF, LOKAL İLERİ EVRE VEYA METASTATİK MEME KANSERİ HASTALARINDA ÇOK MERKEZLİ, TEK KOLLU TRANSTUZUMAB EMTANSİN (T-DM1) ÇALIŞMASI, 2015 - 2017

SAİP P. M., Other International Funding Programs, ErbB-2 Pozitif Lokal Rekürren ya da Metastatik Meme Kanseri İlk Hat Tedavi olarak Neratinib ve Paklitaksel'e Karşı Transtuzumab ve Paklitaksel'in Karşılaştırıldığı faz 3, Randomize, Açık Etiketli, İki kollu çalışma, 2009 - 2012

SAİP P. M., EU Framework Program Project, Erken dönem HER-2/neu – aşırı salınımlı/amplifikasyonlu meme kanserli kadınlarda trastuzumab tedavisi sonrası Neratinib (HKI-272) ile randomize, çift kör, plasebo kontrollü bir çalışma, 2009 - 2012

SAİP P. M., Other International Funding Programs, Lokal rekürren veya metastatik meme kanserli hastalarda Bevasizumab'ın (Altuzan®) birinci basamak tedavide Taksan monoterapisine veya Taksan'lı kombinasyon tedavilerine ek olarak kullanıldığı, açık çalışma, 2007 - 2012

SAİP P. M., Other International Funding Programs, İlerlemiş veya rekürren non-skumöz küçük hücreli olmayan akciğer kanserli hastalarda birinci basamak tedavisi olarak Bevasizumab'ın (Altuzan®) platin içeren kemoterapiyle kombine tedavisinin değerlendirildiği, açık çalışma, 2006 - 2012

Memberships / Tasks in Scientific Organizations

Onkoloji(Tümör Bilimi)Derneği, Member, 2014 - Continues

Türk Tıbbi Onkoloji Derneği, Chairman, 2013 - Continues

Mediterranean Multidisciplinary Oncology Forum, Board Member, 2007 - Continues

European Society for Medical Oncology (ESMO), Member, 2006 - Continues

American society of Clinical Oncology(ASCO), Member, 2000 - Continues

Türk Tıbbi Onkoloji Derneği, Board Member, 2009 - 2013

Metrics

Publication: 163

Citation (WoS): 507

Citation (Scopus): 519

H-Index (WoS): 12

H-Index (Scopus): 12

Congress and Symposium Activities

IV.Ulusal Akciğer Kanseri Kongresi, Attendee, Antalya, Turkey, 2014

Multidisipliner Jinekoloji Onkoloji Kursu, Attendee, İstanbul, Turkey, 2014

İmmüno-Onk?oloji ve Hedefe Yönelik Kanseri Tedavileri Kongresi, Attendee, Antalya, Turkey, 2014

Hedef Kanser Kongresi, Attendee, K.K.T.C, Turkey, 2014

5.Türk Tıbbi Onkoloji Kongresi, Attendee, Antalya, Turkey, 2014

Best Of Asco, Attendee, İstanbul, Turkey, 2013

American Society of Clinical Oncology(ASCO), Attendee, Chicago, United States Of America, 2013

20.Ulusal Kanser Kongresi, Attendee, Antalya, Turkey, 2013

Best Of Asco, Attendee, İstanbul, Turkey, 2012

4.Türk Tıbbi Onkoloji Kongresi, Attendee, Antalya, Turkey, 2012

Non Academic Experience

İ.Ü. Onkoloji Enstitüsü

İ.Ü. Onkoloji Enstitüsü

İ.Ü. Onkoloji Enstitüsü

i.Ü. Onkoloji Enstitüsü (Tıbbi Onkoloji)

Beyoğlu Devlet hastanesi

Beyoğlu Devlet HAstanesi

Sultanahmet Milli Eğitim Sağlık Eğitim Merkezi

Milli Eğitim, Sağlık Eğitim Merkezi